Gilead Sciences, Inc.

Megan K Armstrong

Zheng-Yu Yang

Elbert Chin

Chienhung Chou

Chao-I Hung

James G Taylor

Jeromy J Cottell

Michael L Mitchell

Scott D Schroeder

Gregory Notte

Nathan E Wright

Gediminas J Brizgys

Adam James Schrier

David W Lin

Nathan D Shapiro

Rhiannon Thomas-Tran

Yifan Deng

Prasenjit Kumar Mukherjee

Kavoos Kolahdouzan

James S Cassidy

Laurent P Debien

Ezra Roberts

Shaina V Nguyen

Joshua D Farr

Daniel Roa

Pancham Lal Gupta

Katie A Spence

Benjamin J June

The present disclosure relates generally to compounds that inhibit PRMT5. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through inhibiting PRMT5. The disclosure further relates to the use of the compounds for the treatment of a disease or condition associated with chromosome 9p21 deletion, MTAP null, or any other MTAP deficiency. The disclosure further relates to the use of the compounds for the treatment of cancers.

PRMT5 inhibitors and uses thereof

The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.

GLP-1R modulating compounds

Growing community of inventors

San Francisco, CA, United States of America

Megan K Armstrong